A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate
To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post
radical prostatectomy patients with high risk pathological features for failure. To
determine the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and
clinical progression rate at 5 years.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society